NAMS Prakiraan wutah bathi kanggo taun ngarep newamsterdampharma.com

Lambang korporat lan logo NewAmsterdam Pharma Company N.V. (NAMS)

The earnings per share forecast for next year demonstrates that the current parameter is -28.40. NewAmsterdam Pharma (NAMS) business development relies on the success of clinical trials and regulatory approvals. Stable free cash flow is ensured by patent protection within the metabolic pathology niche. Meanwhile, the active R&D phase for the CETP inhibitor guarantees the company a strong position in the cardiology sector.

NewAmsterdam Pharma N.V. (NAMS): Prakiraan wutah bathi resik saben saham ing taun ngarep saka 21.06.2023 nganti 17.11.2026

NAMS (NewAmsterdam Pharma Company): rincian analitis lan laporan miturut indikator

Analisis wiwitan perusahaan:NAMS, newamsterdampharma.com
Produk dadi NewAmsterdam Pharma Company N.V.

During fundamental asset screening, this indicator serves as a leading signal of market expectations for earnings per share. By analyzing the expected EPS growth for the coming year, an investor can observe a smoothed vector of consensus forecasts, which for NewAmsterdam Pharma (NAMS) directly reflects the potential commercial success of obicetrapib as an affordable alternative to injectable methods for treating hypercholesterolemia.

Analisis perusahaan pesaing

ASND (Ascendis) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi kanggo taun ngarep Madrigal Pharmaceuticals|Prakiraan wutah bathi kanggo taun ngarep CORT|Prakiraan wutah bathi resik saben saham kanggo taun ngarep RYTM (Rhythm Pharma)|Prakiraan wutah bathi resik saben saham kanggo taun ngarep akerotx.com AKRO|Metsera Therapeutics (MTSR) - Prakiraan wutah bathi resik saben saham ing taun ngarep|MLTX - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|CRNX: Prakiraan wutah bathi resik saben saham kanggo taun ngarep|SLNO: Prakiraan wutah bathi kanggo taun ngarep|FOLD - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep 89bio Pharma|Agios Corp (AGIO) - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep structuretx.com (GPCR)|Prakiraan wutah bathi saben saham kanggo taun ngarep mimedx.com MDXG|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Rezolute RZLT|Lexicon Pharmaceuticals, Inc. - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|MBX: Prakiraan wutah bathi saben saham kanggo taun ngarep|Altimmune Corp - Proyeksi tambahing bathi saben saham ing taun ngarep|Aardvark Therapeutics Inc (AARD) - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben siji saham kanggo taun ngarep Sagimet Biosciences SGMT|BIOA (bioagelabs.com) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi saben saham kanggo taun ngarep Biomea Fusion (BMEA)|Prakiraan wutah bathi kanggo taun ngarep QNCX|Proyeksi tambahing bathi saben saham ing taun ngarep GUTS|Prakiraan wutah bathi kanggo taun ngarep VTVT (vTv Therapeutics Inc.)|Dinamika bathi saben saham sing diarepake ing taun ngarep ATPC|Pluristem Therapeutics - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep synlogictx.com SYBX|LPCN: Prakiraan wutah bathi kanggo taun ngarep|Matinas BioPharma Holdings, Inc. - Dinamika bathi saben saham sing diarepake ing taun ngarep|SPRB (Spruce Biosciences Inc.) - Prakiraan wutah bathi kanggo taun ngarep|galecto.com (GLTO) - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Carmell Therapeutics (CTCX)|LUMO (Lumos Pharma Inc) - Dinamika bathi saben saham sing diarepake ing taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep organovo.com ONVO|Radius Health (RDUS) - Prakiraan wutah bathi resik saben saham ing taun ngarep